Nurix Therapeutics, Inc. (NRIX)

Over the past six months, Nurix Therapeutics announced new preclinical data at AACR 2026, reported Q1 2026 financial results with a revenue of $6.3 million and a net loss of $87.2 million, and participated in an investor conference. They also presented research at the AACR 2026 Annual Meeting, reported Q4 and Fiscal Year 2025 financial results highlighting the DAYBreak™ program and a $592.9 million cash position, and presented Phase 1 results for bexobrutideg at ASH. Insider selling occurred in May 2026, and analysts are overwhelmingly bullish with 17 buy ratings. The stock has gained 75.0% over the past 12 months.

There is no specific information available regarding demand seasonality for Nurix Therapeutics' products or services. Demand is likely driven by clinical trial success, regulatory approvals, market access, and disease prevalence, rather than seasonal fluctuations.

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule and antibody therapies. They operate in the Healthcare sector, specifically in the Biotechnology and Drug Discovery industry, leveraging the body's natural protein-disposal system to target previously "undruggable" proteins. Nurix utilizes a proprietary DELigase platform, an AI-integrated discovery engine, to identify and refine potent drug candidates. Key pipeline candidates include NX-5948 (Bexobrutideg), an orally bioavailable BTK degrader in Phase 2 clinical trials; NX-2127 (Zelebrudomide), a dual degrader of BTK and transcription factors in Phase 1a/1b clinical trials; NX-1607, an inhibitor of CBL-B in Phase 1a/1b clinical trials; and multiple preclinical degraders and degrader antibody conjugates (DACs).

Nurix Therapeutics has a strong presence in the United States, with its headquarters and primary research labs in San Francisco, California. They have expanded to include R&D centers in Brisbane, California, and The Woodlands, Texas.

Nurix Therapeutics maintains a positive brand reputation within the scientific and investment communities. They consistently present data at major healthcare conferences, showcasing scientific leadership and pipeline progress. Analysts have a strong "Buy" consensus for the stock, and strategic collaborations with companies like Gilead Sciences enhance its reputation. No significant negative events impacting the company's reputation were found.

Nurix Therapeutics is predominantly owned by institutional investors, holding approximately 109.68% to 115.9% of the outstanding stock. Major institutional owners include BlackRock, Inc., Redmile Group, LLC, and Vanguard Group Inc. Insiders hold a smaller percentage, ranging from 8.20% to 11.05%, while retail investors hold a negligible amount. Third Rock Ventures III LP is the largest individual shareholder.